Medscape Publishes Emulated Randomized Trial Analysis Tuesday July 28, 2026 Using 2018-2023 US Insurance Claims Data Documenting That Adults With Stable Inflammatory Bowel Disease (IBD) and Comorbid Obesity or Diabetes Who Initiated Semaglutide or Tirzepatide Did Not Have a Lower Risk of IBD Relapse or Improved Safety Event Rates Versus Non-Initiators; Cohort 1 (Patients on 5-Aminosalicylates or No IBD-Specific Therapy) and Cohort 2 (Patients on Immunomodulators or Advanced Therapies) Both Reported No Benefit From GLP-1 Receptor Agonist Initiation on IBD Clinical Outcomes
Medscape published an emulated randomized trial analysis on Tuesday July 28, 2026 using US insurance claims data from 2018-2023 to test whether patients with stable inflammatory bowel disease (IBD) and comorbid obesity or diabetes benefit from initiating GLP-1 receptor agonist therapy alongside their ongoing IBD treatment. The researchers used a target trial emulation design comparing patients who initiated semaglutide or tirzepatide with patients who did not. Two cohorts were analyzed: Cohort 1 comprised patients on 5-aminosalicylates or no IBD-related therapy; Cohort 2 comprised patients on immunomodulators and/or advanced therapies (biologics or small molecules). Neither cohort showed a lower risk of IBD relapse or improved safety event rates among GLP-1 initiators. The analysis pushes back against the anti-inflammatory hypothesis advanced in preclinical GLP-1 receptor agonist literature (based on animal-model reductions in gut inflammation) and against the informal clinical assumption that IBD patients with obesity or diabetes may derive an anti-inflammatory benefit from initiating GLP-1 therapy. The clinical implication: prescribers should not initiate GLP-1 receptor agonist therapy in stable IBD patients for the purpose of improving IBD outcomes. GLP-1 initiation for obesity or diabetes in this population remains reasonable when the metabolic indication justifies it independently.